A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, most patients do not respond and current biomarkers (eg, programmed death 1 ligand 1 [PD-L1]), mismatch repair deficiency [dMMR]/high microsatellite i...
שמור ב:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMC
2026-01-01
|
| סדרה: | Journal of Translational Medicine |
| גישה מקוונת: | https://doi.org/10.1186/s12967-025-07378-2 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
